# PEMF Therapy in Veterinary Medicine: What Works
Pulsed electromagnetic field (PEMF) therapy is a non-invasive treatment that delivers pulsed magnetic and induced electric fields into tissue through coils, pads, or blankets. The strongest veterinary evidence supports it as an adjunct for osteoarthritis (OA) pain in dogs and for bone healing, while evidence for soft-tissue wound and tendon repair is weaker and largely preclinical [1].
PEMF is not a drug and not a substitute for analgesia. It is a device-based modality that sits alongside NSAIDs, monoclonal antibody therapy, physiotherapy, and weight management in a multimodal plan. This article reviews what the clinical literature in dogs and horses actually shows, where the evidence thins out, and the practical mistakes that make results hard to interpret.
This article is educational and is not a substitute for veterinary diagnosis or treatment.
## What PEMF Actually Is
PEMF devices generate a time-varying magnetic field. Because a changing magnetic field induces an electric field in conductive tissue, PEMF can influence cell membranes, ion transport, and signaling pathways without touching the patient. Treatment is delivered by inductive coils housed in mats, blankets, wraps, or handheld applicators [1].
Two physical parameters define a PEMF protocol:
- **Frequency**, measured in hertz (Hz), which is how many pulses occur per second.
- **Intensity**, usually expressed in millitesla (mT) or gauss (G), where 1 mT equals 10 G.
A third practical parameter is session duration, typically reported in minutes. These three numbers, plus coil placement and treatment schedule, determine the dose. In veterinary studies they vary enormously, which is the single biggest obstacle to comparing one study with another [1].
### PEMF Is Not TENS, Laser, or Shockwave
These four modalities are frequently lumped together as "therapy" in clinic marketing, and owners often assume they are interchangeable. They are not.
- **TENS (transcutaneous electrical nerve stimulation)** drives electrical current through surface electrodes into skin and nerve. It targets sensory nerve fibers for pain gating. PEMF induces current magnetically, without electrodes, and reaches deeper tissue.
- **Laser therapy (photobiomodulation)** uses light photons at specific wavelengths to interact with mitochondrial chromophores such as cytochrome c oxidase. The therapeutic agent is light, not a magnetic field.
- **Shockwave therapy** delivers high-energy acoustic pressure waves that create mechanical stress at tissue interfaces, used mainly for tendon and bone-tendon conditions. It is mechanical, not electromagnetic.
- **PEMF** uses a pulsed magnetic field as the primary agent.
The distinction matters because evidence for one modality does not transfer to another. A positive laser trial tells you nothing about PEMF dosing or efficacy.
### What PEMF Does at the Cellular Level
Basic science has moved faster than clinical trials. A 2026 study using cell cultures, tissue homogenates, and isolated mitochondria found that PEMF selectively stimulates respiration linked to ATP synthesis, affecting uncoupled respiration less. The authors concluded that changes in ATP synthesis likely underlie the primary beneficial effects observed, and that the exact mechanism still requires clarification [2].
A separate mouse study found that weak, non-ionizing, non-thermal broadband pulsed electromagnetic fields increased the antioxidant potential of blood plasma in a dose-dependent way, by roughly 8% at minimum exposure and 20.6% at maximum exposure compared with unexposed young animals. Mitochondrial fluorescence in thymocytes increased by 29% at maximum exposure [3].
In an inflammatory pain mouse model, researchers tested pulse frequencies of 5, 50, and 75 Hz and durations of 10, 20, and 30 minutes. The strongest antihyperalgesic effect occurred at 75 Hz with 20 or 30 minutes. A 20-minute session at 75 Hz reduced TNF levels in the paw and increased superoxide dismutase activity in the paw and spinal cord, indicating both peripheral and central anti-inflammatory and antioxidant effects [4].
These findings are important because they show that frequency and duration are not arbitrary. Different parameters produce measurably different biological responses, which is exactly why unreported parameters make clinical trials hard to interpret.
## The Clinical Evidence in Dogs
Canine osteoarthritis is where most veterinary PEMF research has concentrated. The results are consistent in direction but variable in magnitude, and several trials have important design limitations.
### Osteoarthritis Pain
A 2025 [randomized clinical trial](/blog/guides/randomized-clinical-trials-design-conduct-and-analysis) evaluated PEMF as a standalone analgesic in 20 client-owned dogs with radiographically confirmed hip OA. The active group received 50 Hz, 40 gauss (4 mT), 30 minutes per session, twice weekly for five weeks. Dogs in the PEMF group showed significant pain reduction from the first session. Canine Brief Pain Inventory scores improved markedly between sessions 1 and 10 (P = 0.01), and Helsinki Chronic Pain Index scores showed similar progress (P = 0.05). No significant differences in joint range of motion or thigh circumference were detected between groups [5].
A separate randomized, double-blind, placebo-controlled trial in 21 dogs with radiographically confirmed OA in at least one limb administered PEMF over six weeks. Treated dogs showed significant improvement in gait symmetry by day 42 (P = 0.030), assessed by kinetic analysis of peak vertical force and vertical impulse. Liverpool Osteoarthritis in Dogs questionnaire scores declined steadily in the treatment group, though between-group differences did not reach significance, and no significant between-group difference was found for the overall treatment effectiveness score [6].
A 2024 randomized, controlled, double-blinded crossover study examined the immediate effect of a single PEMF session in eight dogs with coxofemoral OA. A statistically significant difference (P = 0.03) in stride length of the affected limb was recorded between active and placebo treatments. Within the active treatment, reach (P = 0.04) and stride length (P = 0.047) both became shorter in the affected limb after treatment. Subjective outcome measures showed no statistically significant difference [7]. That direction of change is worth noting: shorter stride and reduced reach after a single session is not the same as clinical improvement, and the small sample size limits interpretation.
A 2013 randomized, controlled, blinded trial of pulsed signal therapy (a related electromagnetic modality) in 60 dogs with moderate-to-severe OA found the treatment group performed significantly better than controls on Canine Brief Pain Inventory Severity and Interference scores (P < .01). Extension (P = .04) and peak vertical force (P = .03) did not remain statistically significant after adjustment for multiple comparisons [8].
### PEMF as an Adjunct to Other Analgesics
A 2026 prospective, randomized, comparative effectiveness trial in 30 dogs with hip OA compared bedinvetmab alone against bedinvetmab plus physiotherapy using photobiomodulation and PEMF. Physiotherapy was performed twice weekly for 90 days. Both groups improved significantly (P < 0.001). In algometry, the combination group showed a significant increase in pain threshold as early as day 15 and was superior to bedinvetmab alone from day 30 (P = 0.027), with more pronounced differences at days 60, 75, and 90 (P < 0.001) [9].
That trial is one of the more informative veterinary datasets because it tests PEMF inside a realistic multimodal protocol rather than as a monotherapy. It supports the idea that PEMF adds measurable analgesic benefit on top of a monoclonal antibody, at least for pressure pain thresholds.
### PEMF Compared With NSAIDs
A 2026 randomized controlled pilot study compared PEMF against mavacoxib in 16 dogs with clinically and radiographically confirmed OA. Dogs received either a 12-session PEMF protocol over 45 days or a standard mavacoxib regimen. PEMF showed earlier improvements in pain, lameness, and muscle mass, with a favorable trend in joint mobility. No significant differences were detected in gait or radiographic parameters between groups. The authors described PEMF as non-inferior to NSAIDs in this small sample and highlighted its potential role in multimodal OA management [10].
Non-inferiority in a 16-dog pilot is a hypothesis, not a license to stop NSAIDs. NSAIDs remain a cornerstone of canine OA management, and the pilot's own authors framed the finding as preliminary.
### A Different Device Class: Pulsed Shortwave Therapy
A 2024 randomized, double-blinded, placebo-controlled 14-day study of 60 dogs with a presumptive OA diagnosis tested a pulsed shortwave therapy device secured near the cervicothoracic spine, with the stated aim of modulating vagus nerve activity to produce a systemic anti-inflammatory response. Forty-nine animals completed the study and no negative side effects were reported. Outcomes were owner-rated behavioral changes and passive range of motion [11].
This is a different device and a different proposed mechanism (systemic neuromodulation rather than local field effects). It should not be pooled with local PEMF trials when judging efficacy.
## The Evidence in Horses
PEMF therapy applied to a horse, illustrating the equine clinical evidence discussed here. Image: MagnaWave, CC BY 3.0, via Wikimedia Commons.
Equine PEMF use is widespread in the sport horse industry, and the published evidence base is thinner than the canine OA literature.
A 2026 study evaluated short-term effects of PEMF on hematological and biochemical parameters in five active sport horses treated with a full-body blanket for five consecutive days at specified frequencies. Blood was collected before and after treatment and 72 parameters were assessed. Most hematological parameters remained stable. Significant alterations were observed in reticulocyte and platelet counts and hemoglobin levels. Blood biochemistry showed greater variability, with notable changes in plasma proteins, bilirubin, uric acid, creatine kinase, creatinine, liver enzymes, and iron-binding capacity. Cortisol and thyroxine did not change significantly. The authors concluded that whole-body PEMF showed no detectable adverse effects over five days on health or stress response, while noting that limited research and inconsistent protocols create uncertainty about efficacy and safety in horses [12].
That study is a safety and physiology study, not an efficacy trial. It does not demonstrate that PEMF treats any equine condition. It does show that five days of whole-body exposure did not produce an obvious stress response, which is useful context for owners considering the modality.
For equine bone healing and OA, the general veterinary review literature supports PEMF as a safe, non-invasive modality with accumulating clinical evidence for bone healing, wound healing, osteoarthritis and inflammation, and post-operative pain and edema [1]. The species-specific equine clinical trial base remains small.
## Indication Versus Evidence
The table below grades the veterinary evidence by indication and species. Grades reflect the strength and consistency of published veterinary clinical data, not marketing claims.
| Indication | Species with best evidence | Evidence grade | What the data show |
|--|--|--|--|
| Osteoarthritis pain | Dog | Moderate | Multiple randomized trials show reduced pain scores, improved gait symmetry, and improved owner-rated function. Effects are consistent in direction but variable in size [5][6][8] |
| Osteoarthritis pain as adjunct | Dog | Moderate | Added benefit on algometry when combined with bedinvetmab and photobiomodulation [9] |
| Fracture and bone healing | Dog, horse, and preclinical models | Moderate (preclinical strong, veterinary clinical limited) | Review literature supports bone healing as a core indication [1]. Rodent models show improved bone mineral density, microarchitecture, and biomechanical strength with PEMF [13] |
| Tendon injury | Horse | Weak | Widely used clinically, but controlled veterinary clinical trials are scarce. Most support is extrapolated from bone and soft-tissue biology |
| Wound healing | Dog, horse | Weak | Review literature lists wound healing as an indication [1], but controlled veterinary wound trials are limited. Rodent gastric ulcer and muscle injury models show pro-healing signaling changes [14][15] |
| Post-operative pain and edema | Dog, horse | Weak to moderate | Supported in review literature [1] but veterinary-specific controlled trials are limited |
Two rodent studies illustrate why the preclinical signal is stronger than the clinical one. In a rat osteosarcopenia model, 15 Hz, 2.0 mT PEMF applied five times per week for 12 weeks improved musculoskeletal outcomes and inflammatory markers [16]. In ovariectomized rats, 50 Hz, 0.6 mT PEMF for 90 minutes daily for six weeks increased whole-body, femoral, and vertebral bone mineral density, improved bone microstructure, and increased femoral maximum load and bending strength [13]. These are controlled laboratory findings in rodents, not dogs or horses.
## Why the Parameters Matter So Much
Frequency, intensity, and duration are the dose. In the canine OA trials alone, protocols included 50 Hz at 40 gauss for 30 minutes twice weekly [5], six weeks of unspecified daily treatment [6], a single session [7], and 12 sessions over 45 days [10]. The equine study used a whole-body blanket at unspecified frequencies for five consecutive days [12]. Rodent studies used 15 Hz at 2.0 mT [16], 50 Hz at 0.6 mT [13], and 8, 50, or 75 Hz at 3.8 mT for one hour daily [17].
The mouse inflammatory pain study is the clearest demonstration that this matters. Testing 5, 50, and 75 Hz at 10, 20, and 30 minutes, the authors found the best antihyperalgesic effect at 75 Hz with 20 or 30 minutes, and identified 75 Hz and 20 minutes as optimal. A 20-minute session at 75 Hz reduced paw TNF and increased superoxide dismutase activity in the paw and spinal cord [4]. A separate mouse knee OA study compared 8, 50, and 75 Hz at 3.8 mT for one hour daily over four weeks. All three frequencies reduced OARSI scores, but 50 and 75 Hz had better positive effects than 8 Hz, and only 75 Hz attenuated synovitis [17].
If a clinic cannot tell you the frequency in Hz, the intensity in mT or gauss, and the session duration in minutes, you cannot compare that protocol with any published trial. That is not a technicality. It is the difference between a defined treatment and an undefined one.
### Equine Devices Are Not Interchangeable With Human Units
Equine PEMF blankets and pads are engineered for a body mass and geometry that differ by an order of magnitude from human devices. Coil size, coil spacing, field distribution across the treatment volume, and the resulting field intensity at depth all differ. A human PEMF mat placed on a horse does not deliver the same field to the same tissue as a purpose-built equine blanket, and the reverse is also true.
The same logic applies to canine and equine devices. A pad designed for a 30 kg dog's stifle does not produce the same field geometry as a full-body equine blanket. When a study reports a frequency and intensity, that number applies to the specific device and coil configuration used. Copying the number onto a different device does not reproduce the dose.
## Practical Implications for Owners
PEMF is generally well tolerated. The canine trials reported no negative side effects [11][5], and the equine study found no detectable adverse effects on health or stress response over five days [12].
A few practical points follow from the evidence:
1. **Ask for the protocol.** Request frequency in Hz, intensity in mT or gauss, session duration, and the treatment schedule. A clinic that tracks these numbers is treating with a defined dose.
2. **Treat it as an adjunct.** The best-supported use in dogs is alongside standard OA management, not instead of it. The bedinvetmab combination trial is the clearest example [9].
3. **Expect functional outcomes, not radiographic ones.** The comparative pilot found no significant differences in radiographic parameters between PEMF and NSAID groups [10]. PEMF is not expected to reverse joint degeneration.
4. **Give it a fair trial window.** The canine OA trials used protocols lasting five to six weeks [5][6]. Judging a modality after one session is not informative, and the single-session crossover study found no significant subjective improvement [7].
5. **Do not use PEMF to delay diagnosis.** Lameness, swelling, and pain have many causes. A device is not a diagnostic test.
## Clinical Relevance, Limitations and Common Mistakes
The clinical relevance of PEMF in veterinary anesthesia and analgesia is real but bounded. It offers a non-pharmacologic option for chronic OA pain in dogs, with several randomized trials showing measurable improvement in validated pain and function instruments [5][6][8]. It appears to add benefit on top of monoclonal antibody therapy [9]. It is safe in the studied populations [11][12]. For bone healing, the mechanistic and preclinical case is strong [1][13], though species-specific veterinary clinical trials remain limited.
The limitations are equally clear. Sample sizes in veterinary PEMF trials are small, ranging from 8 to 60 dogs [11][7][8]. Blinding is difficult when a device produces sensation or sound, and several trials relied partly on owner-completed questionnaires, which are susceptible to expectation effects. Outcome measures differ between trials, so results cannot be pooled. Reporting of device parameters is inconsistent, which prevents dose-response analysis [1].
Common mistakes:
- **Treating PEMF as a replacement for analgesia.** The comparative pilot against mavacoxib was a 16-dog non-inferiority study, and its authors called the findings preliminary [10]. It does not justify withdrawing effective drugs.
- **Assuming all PEMF devices are equivalent.** Frequency, intensity, coil geometry, and treatment volume all shape the delivered dose. Equine and human units are not interchangeable.
- **Confusing PEMF with laser, TENS, or shockwave.** These are different physical agents with different evidence bases.
- **Judging efficacy after one session.** The single-session crossover study found no significant subjective difference between active and placebo [7].
- **Ignoring the rest of the multimodal plan.** Weight management, exercise modification, physiotherapy, and appropriate pharmacologic analgesia remain the foundation of OA care.
What remains uncertain: the optimal frequency, intensity, and duration for each indication and species. The mouse data suggest 50 to 75 Hz outperforms 8 Hz for OA-related outcomes [17] and that 75 Hz with 20 minutes is optimal for inflammatory hyperalgesia [4], but these are rodent models. Whether those parameters translate to dogs and horses is unresolved. The mechanism of action is also not fully mapped, though mitochondrial ATP synthesis effects are a leading candidate [2].
Individual patients vary, and a veterinarian who knows the patient's full history should make treatment decisions.
## Frequently Asked Questions
### What is PEMF therapy used for in veterinary medicine?
PEMF is used mainly for osteoarthritis pain, bone healing, and as an adjunct for post-operative pain and edema. The strongest veterinary clinical evidence is for OA pain in dogs [5][6][1].
### Does PEMF therapy actually work for dogs with arthritis?
Yes, in several randomized trials. Dogs with hip OA showed significant pain reduction on validated pain indices [5], and treated dogs showed improved gait symmetry by day 42 in a separate placebo-controlled trial [6].
### Can PEMF replace NSAIDs or other pain medication?
No. A small pilot suggested non-inferiority to mavacoxib, but the authors described the finding as preliminary and highlighted a multimodal role rather than replacement [10].
### Is PEMF the same as laser therapy or TENS?
No. PEMF uses a pulsed magnetic field, laser therapy uses light, TENS uses electrical current through surface electrodes, and shockwave uses acoustic pressure waves. Evidence does not transfer between them.
### How long does a PEMF session take?
Published canine protocols range from 30 minutes twice weekly [5] to one hour daily for nine consecutive days in a related electromagnetic modality trial [8]. Protocols vary widely and there is no single standard duration.
### Can I use a human PEMF device on my horse?
No. Equine devices are engineered for equine body mass and geometry, and field distribution differs substantially. Human and equine units are not interchangeable.
### Are there side effects of PEMF in dogs or horses?
Reported side effects are minimal. Canine trials reported no negative side effects [11], and a five-day equine whole-body study found no detectable adverse effects on health or stress response [12].
### How long before I see results from PEMF?
In one canine trial, pain reduction appeared from the first session [5]. In another, gait symmetry improved by day 42 of a six-week protocol [6]. Timelines vary with protocol and condition.
## Related Articles
- [Integrative Veterinary Medicine: Combining Conventional and Alternative Therapies](/blog/careers/integrative-veterinary-medicine-combining-conventional-and-alternative-therapies)
- [Lentiviral Vectors: How They Work and Their Uses in Gene Therapy](/knowledge/molecular-biology/lentiviral-vector)
- [Shock Wave Therapy in Veterinary Medicine: Mechanisms and Clinical Use](/knowledge/veterinary-medicine/emergency-critical-care/shock-wave-therapy-veterinary-medicine-mechanisms-clinical-use)
- [Feline Hyperthyroidism: Radioiodine Therapy](/knowledge/veterinary-medicine/clinical-methods/feline-hyperthyroidism-radioiodine-therapy)
- [Monitoring Analgesic Therapy in Horses: A Practical Guide](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-analgesic-therapy-horses-practical-guide)
- [Monitoring Corticosteroid Therapy in Veterinary Dermatology](/knowledge/veterinary-medicine/veterinary-pathology-microbiology/monitoring-corticosteroid-therapy-veterinary-dermatology)
- [Ranitidine in Veterinary Medicine: Uses and Dosing](/knowledge/veterinary-medicine/clinical-pharmacology/ranitidine-in-veterinary-medicine-uses-and-dosing)
- [Pen G: Penicillin G Use in Veterinary Medicine](/knowledge/veterinary-medicine/clinical-pharmacology/pen-g-penicillin-g-use-in-veterinary-medicine)
- [Maggots in Wounds: Risks and Medical Maggot Therapy](/knowledge/veterinary-medicine/emergency-and-first-aid/maggots-in-wounds-risks-and-medical-maggot-therapy)
## Sources
1. [Veterinary applications of pulsed electromagnetic field therapy.](https://pubmed.ncbi.nlm.nih.gov/29775839/)
2. [Interaction of pulsed low frequency electromagnetic field (PEMF) with mitochondria.](https://pubmed.ncbi.nlm.nih.gov/41618092/)
3. [Remote stimulation of mitochondria and the antioxidant potential of thymocytes by weak non-ionizing non-thermal broadband pulsed electromagnetic fields in mouse.](https://pubmed.ncbi.nlm.nih.gov/42078208/)
4. [Optimization of Pulsed Electromagnetic Field Parameters Attenuates Mechanical Hyperalgesia and Selectively Modulates Inflammatory and Oxidative Markers in a CFA-Induced Inflammatory Pain Mouse Model.](https://pubmed.ncbi.nlm.nih.gov/41578891/)
5. [Pulsed electromagnetic field therapy for pain control in dogs with hip osteoarthritis: A randomized clinical study.](https://pubmed.ncbi.nlm.nih.gov/41114882/)
6. [Influence of pulsed electromagnetic field (PEMF) therapy on osteoarthritis in dogs.](https://pubmed.ncbi.nlm.nih.gov/41044566/)
7. [A prospective, randomised, controlled, double blinded, cross-over study on the effect of a single session of pulsed electromagnetic field therapy on signs of hip osteoarthritis in dogs.](https://pubmed.ncbi.nlm.nih.gov/39061091/)
8. [Randomized, controlled clinical trial evaluating the efficacy of pulsed signal therapy in dogs with osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/23278629/)
9. [Bedinvetmab, alone or in combination with photobiomodulation and pulsed electromagnetic field therapy, on pain and quality of life in dogs with hip osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/41824140/)
10. [Pulsed electromagnetic fields vs NSAID therapy in canine osteoarthritis: A randomised comparative pilot study.](https://pubmed.ncbi.nlm.nih.gov/42024032/)
11. [Pulsed shortwave electromagnetic field therapy increases quality of life in canines with symptoms of osteoarthritics.](https://pubmed.ncbi.nlm.nih.gov/38516818/)
12. [Effects of pulsed electromagnetic therapy on the major hematological and biochemical parameters in horses.](https://pubmed.ncbi.nlm.nih.gov/42618257/)
13. [[Experimental study on the treatment of postmenopausal osteoporosis with low-frequency pulsed electromagnetic fields].](https://pubmed.ncbi.nlm.nih.gov/41152178/)
14. [Combined radiofrequency electromagnetic and pulsed magnetic field exposure enhances gastric ulcer healing via eNOS-mediated angiogenesis in young rats.](https://pubmed.ncbi.nlm.nih.gov/42406607/)
15. [Investigation of the efficiency of pulsed electromagnetic field treatment and stretching exercise in experimental skeletal muscle injury model.](https://pubmed.ncbi.nlm.nih.gov/40128672/)
16. [Pulsed electromagnetic field effectively improves musculoskeletal degeneration and inflammation levels in a rat model of osteosarcopenia: an experimental study.](https://pubmed.ncbi.nlm.nih.gov/41972187/)
17. [Effects of Whole-Body Exposure to Pulsed Electromagnetic Field at Different Frequencies on Knee Osteoarthritis.](https://pubmed.ncbi.nlm.nih.gov/40727996/)
